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About the EMCDDA
The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 
is one of the European Union’s decentralised agencies. Established in 1993 
and based in Lisbon, it is the central source of comprehensive information 
on drugs and drug addiction in Europe.
The EMCDDA collects, analyses and disseminates factual, objective, reliable 
and comparable information on drugs and drug addiction. In doing 
so, it provides its audiences with an evidence-based picture of the drug 
phenomenon at European level.
The Centre’s publications are a prime source of information for a wide 
range of audiences including policymakers and their advisors; professionals 
and researchers working in the field of drugs; and, more broadly, 
the media and general public.
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5Introductory note and acknowledgements
In December 2004, the European Council endorsed the EU drugs strategy for the period 2005–12. This set the framework, 
objectives and priorities for two consecutive four-year action plans. In February 2005, the Commission presented the first of 
these action plans for 2005–08 to the Council. It clearly focused on obtaining concrete results in priority areas defined in the 
strategy. The plan was endorsed by the Council in June 2005.
Under the transversal theme of information, research and evaluation, the plan set the objective of producing estimates on public 
expenditure on drug-related issues. This involved Member States and the Commission collaborating to develop compatible 
methodologies on direct and indirect expenditure for drug-related measures, with the support of the EMCDDA.
This Selected issue is one of the results of this collaborative process.
The EMCDDA would like to thank the following for their help in producing this 2008 Selected issue:
• the heads of the Reitox national focal points and their staff;
• the services within each Member State that collected the data;
• the members of the EMCDDA’s Management Board and Scientific Committee;
• Mr John Carnevale and the participants in the Experts meeting on the methodology to estimate drug-related expenditure in 
the European Union, held in Lisbon on 13–14 December 2007, as follows: Mr Fernando Antoñanzas, Mr Henri Bergeron, 
Mr Brice De Ruyver, Ms Anna García-Altés, Mr György Hajnal, Mr Manfred Huber, Ms Marya Hynes Dowell, 
Ms Lucia Kissová, Mr Pierre Kopp, Ms Dana Loziova, Mr Jayadeep Patra, Mr Peter Reuter, Ms Sara Van Malderen and 
Mr Tomas Zabransky;
• the Office for Official Publications of the European Communities.
Three in-depth reviews of topical interest are published as ‘Selected issues’ each year. These Selected issues are based 
on information provided to the EMCDDA by the EU Member States and candidate countries and Norway (participating 
in the work of the EMCDDA since 2001) as part of the national reporting process.
All Selected issues (in English) and summaries (in 23 languages) are available on the EMCDDA website: 
http://www.emcdda.europa.eu/publications/selected-issues.
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7Introduction
Economics is the study of how society uses its limited resources. In today’s world where many priorities coexist, restricted 
resources often mean complex choices. When dealing with policy in relation to the drugs field, decision-makers have a vested 
interest in improving the effectiveness of drug-related strategies and action plans while lowering costs. With all forms of public 
spending under intense scrutiny, it is more important than ever to ensure that the public funds available for tackling drugs are 
serving society’s priorities efficiently. 
Applied economics plays an important role in providing that justification. When a given set of drug policy objectives could be 
achieved in more cost-effective ways, formal economic evaluation can identify alternatives, analyse their quality, consequences 
and costs and finally assess how they contribute to informing the decision-making process. 
A quantification of drug-related public expenditure corresponds to the identification of costs that should be included in 
subsequent economic evaluations from a public administration perspective.
This Selected issue is divided into two sections. Section one briefly reviews some issues on economic evaluation theory that 
are key to understanding the role of public expenditure as a straightforward costing exercise. The second section, in response 
to the European drugs action plan 2005–08, proposes a common European classification system of public expenditure that 
maximises the validity and comparability of results across countries and presents the first estimates of public expenditure 
in Europe.
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9Drug-related economic evaluation: key issues
Efficiency
When setting priorities for decision-making in relation to 
drug policy, a major criterion is achieving greater efficiency, 
as considerations of efficiency are increasingly part of the 
broad political debate on drug policy (Carnevale Associates, 
2008). Efficiency measures whether the available resources 
are used to obtain the best value for money, considering the 
relationship between resource inputs (the costs of labour, 
capital and/or equipment) and either intermediate (e.g. 
number of problematic drug users treated) or final outputs 
(e.g. lives saved, life years gained, percentage reduction 
in crimes committed). To adopt the criterion of economic 
efficiency in terms of drug policy implies that choices are 
taken which maximise the outputs gained from the resources 
allocated to tackling drugs. Inefficiency exists when resources 
could be allocated in a way that would increase the outputs 
produced.
Addressing efficiency through economic 
evaluation 
An economic evaluation has two main features: it deals with 
both inputs (costs) and outputs (benefits) and also concerns 
itself with choices: economic evaluation always involves 
a comparative analysis of alternative courses of action. 
Therefore, any economic evaluation should identify, measure, 
value and compare the costs and outcomes of the alternatives 
being considered. Achieving efficiency requires giving 
priority to those interventions providing the greatest output 
per unit cost. 
Perspectives in economic evaluation 
The perspective of an economic evaluation performed either 
in a society or organisation affects both the range of costs 
and benefits that will be included in the evaluation itself. 
In general it is argued that, for policy purposes, study 
comparability is enhanced by adopting a society-based 
perspective. However, in practice, it may not always 
be possible for all of the relevant costs and benefits 
to be included in an economic evaluation. At the very 
least, economic evaluations should be explicit about the 
perspectives they adopt, and explain and discuss their likely 
influence on the final results. 
Cost studies
It is important to obtain estimates of the costs of problems 
stemming from drug use and responses; in order to make 
informed decisions when allocating scarce resources, 
policymakers must have a sound understanding of the relative 
costs of drug-related interventions. Other things being equal, 
the lower the cost, the more cost-effective a programme or 
intervention will be, or the higher the net economic benefits 
it will generate. The costs included in a given study are 
mainly defined by the study’s perspective, the availability 
of information, and the relative magnitude of the cost 
components. 
A particular perspective on costing: 
public expenditure
The term ‘public expenditure’ refers to the value of goods and 
services purchased/utilised by the general government of a 
state (at central, regional or local level) in order to perform 
each of its functions (i.e. healthcare, justice, public order, 
education, social services) (1). Its quantification is a costing 
exercise undertaken from the government’s perspective.
Public expenditure studies also represent important 
intermediate stages in economic evaluation since they 
provide an understanding of the size and composition of 
the cost of public programmes and interventions devoted to 
tackling drugs.
(1)
(1)  Total public expenditure (or total general government expenditure) is expressed in national currency (in millions) in national accounts and includes government 
expenditure — for example at local, regional and central levels of government, as well as social security funding — under different headings (such as welfare, 
health, education, etc.). National accounts are compiled in accordance with the European System of Accounts (ESA 1995) adopted in the form of a Council 
Regulation dated 25 June 1996 ((EC) No 2223/96) and published in the Official Journal L 310 of 30 November 1996. A consolidated version is available at 
the following address: http://circa.europa.eu/irc/dsis/nfaccount/info/data/esa95/esa95-new.htm
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The long-term goal of any government is to deliver appropriate 
public services to ensure that taxpayers receive value for money. 
An effective framework for planning, control and reporting 
of public spending is a crucial prerequisite for achieving this 
goal. The analysis of a state’s public expenditure provides 
useful information on its government’s ability to spend money 
effectively and efficiently. To prepare an estimate of drug-
related public expenditure from a government’s perspective is a 
different exercise from estimating the social costs of drugs — the 
social perspective. Public expenditure only represents a portion 
of social costs, mainly in the form of direct costs (those for which 
payments are made, typically on the basis of using resources 
in different sectors). Indirect costs (involving a loss in resources: 
e.g. lost productivity costs due to drug-related morbidity and 
mortality) are explicitly excluded, as are costs inherent to private 
stakeholders (e.g. private health-insurance companies).
For drug policy purposes, an analysis of drug-related public 
expenditure might be of more relevance than estimating social 
costs, for an analysis of a government’s budget allocated to the 
drugs issue is a clear indicator of what policies a government 
is using to reduce drug use and related problems, acting as a 
first step to deciding whether the level and composition of those 
policies is adequate (Reuter, 2006). 
Nevertheless, in a recent report for the EMCDDA, Brice 
De Ruyver et al. (2007) concluded that in drug-related 
literature there is no common definition for the terms ‘public 
expenditure’ and ‘social cost’: 
On the basis of the review of public expenditure studies 
and social cost studies it becomes clear that there is 
no common understanding of the meaning of ‘public 
expenditure’ and ‘social cost’. In fact, several concepts 
are used. Sometimes very different concepts are used 
interchangeably. Sometimes the same concept is used, 
yet with a meaning that differs from one study to another. 
(Brice De Ruyver et al., 2007)
The present report therefore aims to provide a clearer definition 
of what public expenditure means in the field of illegal drugs.
am805490Int.indd   210 26/06/08   11:26:21
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An appropriate drug policy relies on the assessment of drug-
related public expenditure on efficiency grounds. This is not 
feasible without giving a preliminary clear and well-defined 
classification system where costs are properly identified. 
Quantifying a government’s drug-related expenditure is 
a first step in formulating an economic evaluation of drug 
policy interventions. This will provide information that can be 
used to determine whether or not intended benefits are being 
achieved. Once developed, a standardised classification 
system for this exercise will provide a useful framework 
for both policy decision-making and public administration 
accountability. 
As part of the EMCDDA’s input to the EU drugs action 
plan 2005–08, this section aims to quantify current public 
expenditure in the field of drugs in the EU with a unified and 
common classification approach that maximises the validity 
and comparability of results across countries. 
Since government expenditure reflects collective choices 
stemming from political processes and this varies from one 
country to another, international comparisons of public 
expenditure can only provide limited results. Many policy 
initiatives are unlikely to be easily transferable across 
countries in light of the different political, social and 
economic contexts that exist. However, some evaluation 
of the economic consequences of the way these choices 
interact with institutional arrangements and other economic 
and social environmental aspects should be possible. 
Moreover, drug-related expenditure by country may offer a 
useful starting point for international benchmarking on drug 
policy funding (see also Limitations of the study and future 
developments). 
The EMCDDA classification in relation to drug-related 
expenditure has two components: ‘labelled’ and ‘non-
labelled’ expenditure. 
Labelled expenditure
Labelled drug-related expenditure is the ex-ante planned 
expenditure that reflects the voluntary commitment of the 
state in the field of drugs. Labelled expenditure can be traced 
back by a detailed review of budget and/or fiscal year-end 
accountancy reports for an implemented/executed budget. 
The budget is one of the most important policy documents 
produced by governments, for it represents the concrete 
implementation of political objectives. 
Ideally, all public expenditure on drug-related matters should 
feature as labelled expenditure in government budgetary 
documents with budget documentation covering all 
implemented drug-related activities. In general, the budget is 
a financial reflection of a government’s policy: if the budget 
does not include labelled expenditure on drug-related issues, 
there is no guarantee that scarce resources are allocated 
efficiently and that proper control and public accountability is 
enforced. 
However, in practice this situation is confounded by three 
important facts: (1) drug-related programmes and activities 
can be found at many different government levels; (2) drug-
related expenditure is frequently embedded in programmes 
with broader goals; and (3) the reactive nature of some drug-
related expenditure. 
On the whole, the structure of general government consists 
of a central government and sub-national governments 
(i.e. regional and local, according to country) that usually 
manage independent budgets whose size and nature 
vary, according to the political configuration of the country 
concerned. In addition, in some countries, a significant 
share of government expenditure is managed through 
special procedures (e.g. revolving funds, external loans, 
counterpart funds, budgets of autonomous agencies, special 
accounts managed by some ministries). It is not unusual to 
see expenditure managed through sub-national governments 
or by ‘special arrangements’ that do not feature in the 
main government budget, but are managed through extra-
budgetary funds. 
Here again, government budget documents should 
consolidate all drug-related operations managed by general 
government, even if each government and public sector 
entity may have its own drug budget. The health, social and 
economic components of the drug phenomenon help explain 
why important amounts of public expenditure are embedded 
in broader programmes; for example, consequences of drug 
use and trafficking (police or law court services) cannot be 
Drug-related public expenditure in Europe
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easily forecasted and are thus not susceptible to having 
separate budget lines in appropriations. The amount of 
these forms of embedded expenditure can only be estimated 
through modelling approaches that will be discussed later 
under the non-labelled expenditure part of this report.
Methodology
The EMCDDA coordinates a network of national focal points 
(NFPs), named Reitox, set up in the 27 EU Member States, 
Norway, and the candidate countries. Commissioned each 
year by the EMCDDA, the Reitox network produces reports 
that draw an overall picture of the drug phenomenon at 
national level in each EU Member State, Norway and the 
candidate countries. These data provide key information to 
the EMCDDA and are one of the main resources used for 
compiling its Annual report. 
National drug-related expenditure was initially identiﬁ ed by the 
Reitox NFPs as part of the national reporting exercise for 2007.
Labelled expenditure
Reitox NFPs were asked to list any budgeted labelled drug-
related fund (including goods and services) found after 
reviewing central, regional and local government budgets 
(or year-end reports) for the ﬁ scal year 2005. When the 
accounting period concerned a different ﬁ scal year, a rate of 
6 % was used by the EMCDDA to adjust for the occurrence of 
ﬁ nancial costs over time (1) (2). 
Each identiﬁ ed budgeted fund was then classiﬁ ed by the NFP 
within a COFOG function (1st and 2nd levels) (see box on 
page 16), and within a drug programme division (Prevention, 
Treatment, Enforcement, Harm reduction) as deﬁ ned by Reuter 
(see box on page 18).
Non-labelled expenditure
Wherever possible, NFPs were encouraged to explore and 
suggest possible deﬁ nitions of ‘attributable proportions’ 
suitable to estimate non-labelled drug-related expenditure 
under the following selected COFOG groups (2nd level): 
Police services; Law courts; Prisons; Medical products, 
appliances and equipment; Outpatient services; Hospital 
services; Public health services.
(1)  This is the financial discount rate suggested by the Guide to cost benefit 
analysis of investment projects (page 104) for 2001–06 prepared 
for the Evaluation unit, DG Regional Policy, European Commission 
(available at: http://ec.europa.eu/regional_policy/sources/
docgener/guides/cost/guide02_en.pdf).
(2)  The Czech Republic, Germany, Estonia, Lithuania and Romania 
reported on 2006. Belgium and the Netherlands reported on 2004 
and 2003, respectively. The United Kingdom data is for the UK 
financial year ending 31 March 2006.
Total labelled expenditure
Table 1 provides a snapshot of overall budget allocations 
to drug-related issues in Europe. 21 out of 30 countries 
(27 EU Member States, two candidate countries and 
Norway) reported on detailed drug-related labelled 
expenditure for 2005 (see box for methodological details), 
and nine of them gave no information. The table shows the 
total drug labelled amounts (2) reported by country for 2005 
as a percentage of total general government expenditure in 
decreasing order.
Overall, the amount of expenditure reported totalled EUR 
2.42 billion (3). Three countries (the United Kingdom, 
France and Ireland) accounted for the majority (81 %) of 
these expenses in absolute terms. In relative terms, 57 % 
of the countries reported labelled expenditure equal to or 
above 0.05 % of total public expenditure. Ireland was the 
country with the highest proportion of expenditure of this 
nature (0.32 %), followed by Malta (0.23 %) and the United 
Kingdom (0.18 %). 
These results suggest that labelled items amount to only a 
marginal percentage of actual total drug-related expenditure. 
As stated by a preliminary study on public drug-related 
expenditure in Luxembourg (Origer, 2002), there can be 
several reasons for this: budget lines may be too generic to 
be properly identified as labelled drug expenditure, or too 
aggregated, over-inclusive, or simply unidentifiable as such. 
For example, in Slovakia various budgetary and financial 
documents were studied for the present exercise (e.g. 
financial statements submitted to the government, budgets 
and year-end reports of central state administrative bodies, 
annual reports of various institutions working in the field of 
drugs). Although documents at central level give values for 
financial movements in the budgetary year, expenditure is 
usually reported in total, with no detail as to whether this was 
drug-related. Consultation with experts and the Ministry of 
Finance confirmed that such information was not available. 
Similarly, it may also be necessary to distinguish between 
labelled expenditure that is published and that which is not 
published. In Ireland, the present exercise showed that details 
of only around 18 % of labelled expenditure are published. 
The remaining 82 % is either subsumed under, but clearly 
identifiable in, some larger published budget, or it is a clearly 
defined drug-related programme or activity that receives 
funding from a range of different labelled budgets. Many 
departments and agencies involved in drug-related matters 
(1)
(2)  The costs identified in this report are all financial or accounting costs. Financial costs (expenditure) are the actual amounts spent on resources and are important 
in programme planning and budgeting as revenues must be generated to cover these financial outlays in order to sustain programmes. Nevertheless, the 
financial costs of resources may not reflect their real value for society. Financial costs do not aim to measure opportunity costs, or the benefits foregone by a 
particular use of resources. In theory, resources used in economic evaluations should be valued at opportunity costs. This is a complex task, therefore financial 
costs tend to be used instead (Palmer and Raftery, 1999). 
(3)  It is important to highlight that discrepancies reported between financial data collected early in the budget cycle and later reports on actual outturns, indicate 
that financial reports are a more accurate indicator of the actual level of labelled public expenditure than budgetary sources.
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do not currently have adequate reporting systems in place to 
capture and report this budgetary complexity. However, the 
data is potentially available, particularly in relation to direct 
expenditure by government bodies.
A full and comprehensive study containing information from 
regional and local agencies would nevertheless be beyond 
the present resources of most NFPs. For example, according 
to the United Kingdom NFP, much of the expenditure data in 
the United Kingdom is aggregated at programme level and, 
without a detailed analysis of local expenditure documents, is 
difficult to classify using broad headings. 
In addition, drug services usually do not stand in isolation 
and form part of many publicly-funded programmes including 
education and crime reduction and other services that 
provide support to problem drug users. For instance, in 
England, the 2003/04 Budget allocated EUR 28.9 million 
additional funding in recognition of the need to provide extra 
support to jobseekers who are problem drug users. While this 
activity continues, there is no requirement to report how much 
of this expenditure is directed exclusively towards meeting 
the needs of problem drug users and therefore the United 
Kingdom NFP was unable to include such figures in the 
analysis of labelled expenditure. 
In some countries, the vast majority of information on public 
expenditure is limited to a secondary analysis of available 
data. The German health system, for example, is highly 
fragmented and the data regarding drug-related issues is 
distributed across a large number of institutions and data-
carriers and is in part subject to stringent data-protection 
laws. This fragmentation is furthermore associated with 
limitations regarding the comparability and interpretation 
of results. Over and above these problems related to the 
fragmented health system, also the strong federal 
structure (as in other countries) with the basic principle 
of subsidiarity causes difficulties in calculating an overall 
picture from a central perspective. As responsibility for 
health issues lies within the responsibility of the 16 regions 
(‘Länder’), different systems of accounting and budgeting 
and even different setting of priorities will make the attempt 
to calculate national figures very ambitious. Beside federal 
and regional level, the partners of the German social 
insurance funds also play an important role, especially 
within the treatment area. To account for all these major 
sources of information requires considerable means and time 
not available for the preparation of this study. An additional 
limitation in Germany is that the information published by 
public institutions involved in drug issues usually does not 
distinguish between licit and illicit substances, providing 
overall estimates of, for example, all psychological and 
behavioural disorders caused by psychotropic substances 
(F10 – F19 ICD10 diagnosis) (4).
To be able to record such varied types of data would require 
shifts in general government accounting practices, for 
example moving towards an output focus when preparing 
the government’s annual estimates and disclosing details of 
expenditure currently classified with highly generic labels. 
Hopefully, budgeting and reporting arrangements on 
drug-related matters in the public sector will become more 
apparent in the coming years as all government financial 
(1)
(4)  International Classification of Diseases, 10th Revision (ICD-10), 2007 version. World Health Organization, Geneva. 
 http://www.who.int/classifications/apps/icd/icd10online/
Table 1: Total labelled expenditure reported by country 
 
 Amount Amount as a proportion
 (EUR million) of total public 
  expenditure (%) (1)
Ireland 176.8 0.32
Malta 4.9 0.23
United Kingdom 1 463.8 0.18
Denmark 119.1 0.11
Poland 107.0 0.10
Portugal 69.1 0,10
Luxembourg 9.8 0.08
Greece 53.4 0.06
Slovenia 7.5 0.06
Estonia 1.9 0.05
Cyprus 3.2 0.05
Lithuania 3.5 0.05
Romania 13.5 0.04
Czech Republic 16.9 0.04
France 315.4 0.03
Slovakia 1.9 0.01
Finland 8.0 0.01
Germany 35.5 (2) 0.003
Austria 4.0 (3) 0.003
Hungary 1.0 0.002
Croatia 7.2  n.a.
(1)  Total general government expenditure in 2005. Source: Eurostat
Source of data other than (1): Reitox national reports, 2007. 
(2)  The source for this information was the national report provided by 
Germany. This amount of money only covers expenditure within the 
Federal Ministry of Health covering expenses of the Federal Drug 
Commissioner. Expenditure for treatment, law enforcement and 
prevention is not included.
(3)  Most of the expenditure in Austria is in regional and local budgets 
and was therefore not collected as part of this exercise.
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issues gain in accessibility. In Ireland, for example, it is 
anticipated that a Management Information Framework will 
be introduced; one of its main roles will be to improve the 
management of resources once allocated, and to provide 
for increased clarity and accountability in the use of these 
resources. Annual output statements are to be published by 
government departments, and will match key outputs and 
strategic impacts to financial and staffing resources. 
Nevertheless, as stated by the Luxembourg NFP, drug-related 
public expenditure identification is feasible, although this 
requires a considerable amount of analytical work, including 
the analysis of budget and year-end report documents, 
clarification meetings with financial authorities, qualitative 
interviews, analysis of activity reports, financial statements 
of ministerial departments and other public bodies’ statistical 
registers, to name but a few. In addition, researchers may 
need to decide themselves on whether to include certain 
types of expenditure. It is therefore important that such 
decisions are taken according to standards that can be 
replicated, using harmonised and broadly recognised 
methodological benchmarks, guidelines and classification 
systems.
Regional and local labelled expenditure
Most of the countries reported labelled expenditure at 
central government level. Only six (Czech Republic, 
Denmark, Germany, Estonia, France, Poland) accounted 
expenses at regional and/or local government level 
(Figure 1). These regional and local expenses represent 
a very small proportion — 9 % — of the total labelled 
expenditure identified. The Czech Republic was the only 
country to provide details on both regional and local 
budgets (representing 19 % and 10 % of the total budget 
respectively), with the information coming mainly from the 
annual reports of drug policy implementation in regions, 
which were prepared by regional drug coordinators and 
submitted to the Secretariat of the Council of the Government 
for Drug Policy Coordination. 
As already expressed, at the time of drafting this report, most 
NFPs could not carry out a full and comprehensive analysis of 
all levels of government expenditure, hence efforts focused on 
assessing labelled expenditure from central government. This 
explains the lack of detail on local and regional government 
expenditure which does not reflect the role really played by 
regions and local communities in providing public services 
related to drugs. For instance, in Germany, the total labelled 
expenditure identified at Länder level tends to be higher than 
at federal level.
In Ireland, there is no regionally or locally-funded drug-
related public expenditure. Instead, funds are voted via the 
national parliamentary ‘Estimates’ process for allocation 
by government departments or agencies for use at regional 
and local levels. Coding this funding according to level 
of government rather than according to the function of the 
voluntary or community-based recipient of the funding may 
lead to an under-representation of activities carried out at 
regional or local level. For example, while a large portion 
of public money may be voted for central government 
support for community development, this same money may 
then be disbursed for expenditure to a range of regional 
or local programmes or projects, which may be coded to a 
specific health-related or education-related activity. As this 
type of expenditure represents a significant portion of drug-
related public expenditure in Ireland, the issue needs to be 
addressed. One solution might be to record the expenditure 
according to both government and non-government 
activities, but the risk of double-counting would need to be 
managed. 
In Finland, the state participates in financing municipal 
expenditure through the transfer of revenues. Consequently, 
municipalities as producers of healthcare services are not 
the sole payers of the service. Municipalities bear around 
75 % of public sector health service costs. The remainder 
is paid by the state administration. In some instances, it is 
impossible to make a precise breakdown with regard to the 
end payer. For instance, when making cost calculations, it 
is difficult to classify projects co-funded by several actors. 
Finland identified EUR 73 million (41 % of total identified 
expenditure) as being allocated to costs resulting from drug 
use incurred by municipalities. Here also, it is vital to make 
sure expenditure is not counted more than once. 
Figure 1: Labelled drug expenditure (in percentages) by level of 
government
 Central Regional and local
Czech Rep
Denmark
Germany
Estonia
France
Poland
 0 10 20 30 40 50 60 70 80 90 100%
Source: Reitox national reports, 2007.
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In the United Kingdom, responsibility for the drug strategy 
lies with a number of departments with the Home Office 
providing the overall lead. Devolution of powers to 
administrations in Northern Ireland, Scotland and Wales 
means it is increasingly difficult to produce a United Kingdom 
national estimate of drug-related expenditure. This is 
compounded by devolution of spending to local level across 
the United Kingdom. In any case, the UK did report budgets 
which were spent locally in accordance with local priorities, 
although they were allocated from national funds. 
Last but not least, Belgium reported aggregated figures at 
various government levels: Federal government accounted for 
73 % of the total expenditure reported, with the remaining 
27 % coming from outlays by towns and municipalities 
(21 %) and regions (6 %).
The COFOG classification system
The main challenge of comparing budget expenditure for 
international benchmarking across countries at a given time 
is consistency. Consistency is also important when making 
comparisons of expenditure within a country over time. 
For the present exercise, we therefore proposed using a 
consistent categorisation system based on the international 
Classification of the Functions of Government (COFOG). 
COFOG is a detailed classification of the functions, or 
socioeconomic objectives, that general government units 
aim to achieve through a range of outlays. Experience has 
shown this system to be relevant and amenable to a wide 
variety of analytic applications. The COFOG classification has 
three structure levels (See box on page 16): at the first level, 
government expenditure is broken down into 10 functions. 
These are each divided into 69 groups (second level of 
COFOG), which are themselves divided into classes, the most 
detailed classification level. COFOG permits an examination 
over time of trends in government outlays on particular 
functions. Conventional government accounts are not usually 
suitable for this purpose because they reflect the organisational 
structures of governments. Not only might time series’ be 
distorted by organisational changes, but at a specific time 
some organisations may be responsible for more than one 
function, and the responsibility for one function might be 
divided among several organisations. COFOG is also used 
for making international comparisons of the extent to which 
governments are involved in economic and social functions. 
Just as COFOG avoids the problems of organisational 
changes in a single government, so too does it avoid the 
problems of organisational differences among countries. 
In an area like drug-related public expenditure where 
there is agreed functional classification, adopting COFOG 
instead of customising a brand new classification presents 
some advantages. COFOG is an international standard 
implemented by the European System of National and 
Regional Accounts (ESA 95) (European Commission, 2002) 
and the definition of its categories is clearly established and 
easily accessible (United Nations, 2008).
Overall labelled expenditure by COFOG function
Ten countries (Czech Republic, Ireland, France, Luxembourg, 
Hungary, Poland, Portugal, Slovakia, Finland, United 
Kingdom) yield labelled expenditure classified according 
to COFOG functions (Table 2). It should be noted here that 
COFOG is not fully implemented in some countries (i.e. 
Czech Republic), thus data provided had to be re-classified 
by NFPs. As expenditure is often programme or funding 
stream based, it can be categorised under a number of 
COFOG headings. Three countries explicitly reported 
difficulties in making the COFOG classification, for example 
the United Kingdom had problems classifying EUR 91 million 
(6 %) of the total expenditure provided.
Overall, of the total labelled expenditure categorised by the 
10 reporting countries, 95 % came within the government 
functions of health (67 %), public order and safety (22 %) 
and general public services (5 %).
By country, health expenditure captured the highest 
proportion of labelled disbursement in all of the 10 reporting 
states, except Slovakia (7 %). Finland (100 %), Portugal 
(93 %), Hungary (90 %) and France (87 %) were those with 
the highest proportions under this function. Labelled health 
expenditure in the remaining countries (Czech Republic, 
Ireland, Luxembourg, Poland, United Kingdom) ranged 
from 49 % to 66 %. The Czech Republic, Luxembourg and 
Poland showed the highest proportions of outlays on public 
order and safety (ranging from 34 % to 37 %), followed by 
the United Kingdom (24 %) and Ireland (16 %). No labelled 
expenses were identified in this function by France, Hungary, 
Slovakia and Finland.
The general public services function covered 12 %, 6 % 
and 4 % of labelled expenditure in France, Ireland and the 
United Kingdom respectively. The majority (93 %) of labelled 
expenses from Slovakia fell under the general public services 
function, however this same function only accounted for 
a meagre 0.7 % in Luxembourg, and nothing in the other 
countries (Czech Republic, Hungary, Poland, Portugal, 
Finland).
Ireland was the only country providing labelled expenditure 
within the functions of housing and community amenities 
(21 %), and economic affairs (7 %). Social protection only 
captured labelled expenditure in Hungary (10 %) and the 
United Kingdom (0.9 %). Defence labelled expenditure was 
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identified only in France (0.3 %) and Portugal (0.1 %), and 
education expenses only in the United Kingdom (1.3 %). 
Labelled expenditure for public order and safety
Six countries (Czech Republic, Ireland, Luxembourg, Poland, 
Portugal, United Kingdom) reported labelled expenditure 
for the public order and safety COFOG function (Table 3), 
adding up to a total amount of EUR 480 million. Of this total, 
31 % corresponded to prisons, 16 % to police services and 
0.06 % to law courts. More than half (54 %) was spent in 
the administration, operation or support activities relating 
to public order and safety affairs and services. By country, 
100 % of expenditure in Luxembourg came under this last 
category, and the majority of expenditure identified in the 
Classiﬁ cation of the Functions of Government (COFOG) 
by functions (1st level) and groups (2nd level)
gf01 General public services
gf0101  Executive and legislative organs, ﬁ nancial and ﬁ scal 
affairs, external affairs
gf0102 Foreign economic aid
gf0103 General services
gf0104 Basic research
gf0105 R&D General public services
gf0106 General public services n.e.c.
gf0107 Public debt transactions
gf0108  Transfers of a general character between different 
levels of government
gf02 Defence
gf0201 Military defence
gf0202 Civil defence
gf0203 Foreign military aid
gf0204 R&D Defence
gf0205 Defence n.e.c.
gf03 Public order and safety
gf0301 Police services
gf0302 Fire-protection services
gf0303 Law courts
gf0304 Prisons
gf0305 R&D Public order and safety
gf0306 Public order and safety n.e.c.
gf04 Economic affairs
gf0401 General economic, commercial and labour affairs
gf0402 Agriculture, forestry, ﬁ shing and hunting
gf0403 Fuel and energy
gf0404 Mining, manufacturing and construction
gf0405 Transport
gf0406 Communication
gf0407 Other industries
gf0408 R&D Economic affairs
gf0409 Economic affairs n.e.c.
gf05 Environment protection
gf0501 Waste management
gf0502 Waste water management
gf0503 Pollution abatement
gf0504 Protection of biodiversity and landscape
gf0505 R&D Environmental protection
gf0506 Environmental protection n.e.c.
gf06 Housing and community amenities
gf0601 Housing development
gf0602 Community development
gf0603 Water supply
gf0604 Street lighting
gf0605 R&D Housing and community amenities
gf0606 Housing and community amenities n.e.c.
gf07 Health
gf0701 Medical products, appliances and equipment
gf0702 Outpatient services
gf0703 Hospital services
gf0704 Public health services
gf0705 R&D Health
gf0706 Health n.e.c.
gf08 Recreation, culture and religion
gf0801 Recreational and sporting services
gf0802 Cultural services
gf0803 Broadcasting and publishing services
gf0804 Religious and other community services
gf0805 R&D Recreation, culture and religion
gf0806 Recreation, culture and religion n.e.c.
gf09 Education
gf0901 Pre-primary and primary education
gf0902 Secondary education
gf0903 Post-secondary non-tertiary education
gf0904 Tertiary education
gf0905 Education not deﬁ nable by level
gf0906 Subsidiary services to education
gf0907 R&D Education
gf0908 Education n.e.c.
gf10 Social protection
gf1001 Sickness and disability
gf1002 Old age
gf1003 Survivors
gf1004 Family and children
gf1005 Unemployment
gf1006 Housing
gf1007 Social exclusion n.e.c.
gf1008 R&D Social protection
gf1009 Social protection n.e.c.
Source: Eurostat.
n.e.c. — not elsewhere classified
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United Kingdom (64 %). Prison-related expenditure was 
provided by the United Kingdom (35 %), the Czech Republic 
(25 %) and Ireland (17 %). Police services accounted for 
100 % of the total amount reported in Poland and Portugal 
and 82 % and 75 % in Ireland and the Czech Republic 
respectively. The United Kingdom identified 0.7 % of its 
labelled public order and safety expenditure in this category 
(i.e. most was included in non-labelled expenditure). 
Regarding law courts, Ireland was the only country reporting 
a tiny portion (1 %) in this category.
Labelled expenditure for health
Labelled expenditure for the health COFOG function 
was reported by 10 countries (Czech Republic, Ireland, 
France, Luxembourg, Hungary, Poland, Portugal, Slovakia, 
Finland, United Kingdom) (Table 4). The total amount 
reported was EUR 1.38 billion, the highest proportion 
being under outpatient (68 %) and hospital services 
(16 %), followed by medical products (7 %) and public 
health services (7 %). 
Two countries, the United Kingdom and Luxembourg, 
placed the majority of labelled health expenditure under the 
outpatient services category (98 % and 89 %, respectively). 
The other countries, except Portugal (2 %), did not report 
outlays in this group.
Hospital services accounted for the highest proportion of 
labelled expenses in Poland (87 %) and France (59 %) 
and a modest figure in Portugal (2 %). Medical products 
expenses were only provided in France (32 %), Poland 
(13 %) and Luxembourg (5 %) and the United Kingdom 
(0.2 %). All the expenditure on health by Hungary, and 
a majority in Portugal (96 %) related to public health 
services. 
Finland reported only on R&D expenses and the majority 
of Slovakia’s labelled expenditure for health were 
disbursements which cannot be assigned to the former 
categories. It was not feasible for Ireland to break down 
its expenditure for the COFOG health function for 2005 
 
 
Police
services
Law
courts Prisons
Public 
order and 
safety not 
elsewhere 
classified
Czech 
Republic
4.3 – 1.4 –
Ireland 23.7 0.3 5.0 –
Luxembourg – – – 3.8
Poland 40.0 – – –
Portugal 4.4 – – –
United 
Kingdom
2.8 – 140.0 254.2
Source: Reitox national reports, 2007.
Table 2: Labelled expenditure reported by COFOG, 1st level (EUR million) 
General 
public 
services
Defence
Public 
order and 
safety
Economic 
affairs
Housing 
and 
community 
amenities
Health Education Social protection
Czech Republic – – 5.8 – – 11.1 – –
Ireland 11.3 – 29.0 13.5 37.2 85.8 – –
France 39.3 1.0 – – – 275.1 – –
Luxembourg 0.1 – 3.9 – – 5.9 – –
Hungary – – – – – 0.9 – 0.1
Poland – – 40.0 – – 67.0 – –
Portugal – 0.1 4.4 – – 64.6 – –
Slovakia 1.8 – – – – 0.1 – –
Finland – – – – – 8.0 – –
United Kingdom 64.9 – 352.0 – – 923.3 19.2 13.2
Source: Reitox national reports, 2007.
Table 3: Labelled expenditure reported by COFOG, 
2nd level – Public order and safety (EUR million)
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Medical
products
 Outpatient
services
Hospital
services
Public health
services
R&D
Health
Health not 
elsewhere classified
Czech Republic – 11.1 – – – –
Ireland – – – 3.8 – –
France 87.0 – 162.3 25.8 – –
Luxembourg 0.3 5.2 – 0.2 0.1 –
Hungary – – – 0.9 – –
Poland 8.6 – 58.3 – 0.1 –
Portugal – 1.0 1.4 62.1 – –
Slovakia – – – – – 0.1
Finland – – – – 8.0 –
United Kingdom 2.0 920.6 – 0.1 0.3 15.5
Source: Reitox national reports, 2007.
below the first level, as the national health services and 
the accounting system were completely reorganised in that 
year. The health expenditure in Ireland in 2005 reported at 
COFOG 2nd level was expenditure by the Department of 
Education for Science for public health services. 
The figure provided by the Czech Republic refers to medical 
products, outpatient services and hospital services in total. 
Available data did not detail the split of expenditure between 
these categories. Similarly, the public health services figure 
for the United Kingdom only refers to expenditure on syringe 
exchange services in Northern Ireland.
The Reuter programme classification 
of labelled expenditure
According to the different needs for policy formulation, 
reporting and budget management, public expenditure 
can be classified according to multiple classes other than 
function (e.g. organisation, fund type, economic category, 
line-item, programme). A programme is a set of activities that 
meet the same specific objectives. In contrast to COFOG, 
a classification by programme takes into account the 
government’s policy objectives and how these policies will 
be implemented. Function and programme categorisations 
are suitable for both policy analysis and formulation and 
performance accountability (Allen and Tomasi, 2001). 
Reuter (2006) has recently proposed a drug-specific 
programme division that considers for its definition the likely 
effects of the programme itself. Hence, labelled expenditure 
was classified further by the reporting countries using the 
Reuter programme division (see box). Eight of them tried 
using the Reuter classification (Ireland, France, Luxembourg, 
Hungary, Portugal, Slovakia, Finland, United Kingdom) 
(Figure 2). Overall, 62 % of their labelled expenditure (EUR 
1.27 billion) was classified according to the system’s four 
categories with treatment being the most frequent type of 
programme financed (77 %), followed by enforcement 
(12 %), prevention (10 %) and harm reduction (1 %).
Reuter’s drug programme division
Prevention programmes: reduce initiation or the probability 
of progress from experimental to regular drug use, either by 
persuasion or by reducing the accessibility of drugs for novice 
users.
Treatment programmes: reduce drug use by experienced 
users through direct individual service (e.g. medical and 
counselling services).
Enforcement programmes: programmes aimed at trafﬁ ckers 
and producers to shift up the supply curve for drugs; other 
things being equal, they should raise the price of drugs and 
lower quantity. Programmes aimed at users and retailers raise 
the transaction costs of buying drugs; those efforts shift the 
demand curve downwards and lower prices and quantities. 
Harm reduction programmes: seek explicitly to reduce the 
adverse consequences of drug use. There are two categories: 
harm prevention aims to reduce the risk of harm conditional 
on drug; harm amelioration aims to reduce the severity of 
speciﬁ c harms after their occurrence (e.g. treatment of HIV 
positive patients, psychiatric treatment for co-morbidities). 
Source: Reuter (2006).
Table 4: Labelled expenditure reported by COFOG, 2nd level – Health (EUR million)
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By country, treatment programmes had the highest proportion 
of labelled expenditure in Slovakia (100 %), the United 
Kingdom (79 %), Portugal (69 %) and Ireland (34 %). Finland 
(100 %) and Hungary (90 %) had their main expenses in 
prevention, and France and Luxembourg in enforcement 
(100 % and 82 % respectively).
Difficulties in implementing both COFOG and 
Reuter classifications
Countries experienced some difficulties when classifying 
budget items according to COFOG or Reuter categorisations. 
Budget reports often list expenditure items according to the 
administrative unit in which they occurred, however in many 
cases countries lacked the information needed to make the 
classification.
For example, in the United Kingdom, much of the expenditure 
data is aggregated at programme level and, without a 
detailed analysis of local expenditure documents, it is 
difficult to classify using broad headings. The monitoring 
of United Kingdom drug-related expenditure is often linked 
to programme expenditure which presents difficulties when 
trying to disaggregate programme components into COFOG 
categories. As expenditure is often programme or funding 
stream based, it can be categorised under a number of 
headings. An illustration of this is the 2005/06 Partnership 
Grant for funding substance misuse work for young people 
in England. This was funded by the Home Office, the 
Department of Health, the Department for Children, Schools 
and Families, and the Youth Justice Board, and financed 
activities such as prevention, education support and advice 
services and treatment. Funds were distributed amongst 
local partnerships throughout England and could be used 
by them to finance a number of activities to address local 
needs. Similarly, in Wales national expenditure is recorded 
at the level of allocations to Community Safety Partnerships 
(CSPs). CSPs are responsible for tackling substance misuse 
and delivering substance misuse local action plans. Spending 
is determined at local level and the classification of drug-
related expenditure is only possible by examining budgetary 
documents at this level. Similar problems are encountered 
when examining spending in Northern Ireland. Such detailed 
analysis requires time and resources and therefore added to 
the burden of this task for the United Kingdom focal point.
Similar difficulties to the COFOG categorisation were found 
when using Reuter’s taxonomy of drug-related expenditure. 
For example, local action plan expenditure in England 
contains elements of treatment, prevention and harm 
reduction, which are difficult to disaggregate. Furthermore, 
some types of expenditure, such as research and information, 
policy and strategy and overseas drug-related assistance 
cannot be classified under the four programme divisions 
without a detailed examination of each project. National 
spending is often grouped by programme or funding stream 
making it difficult to disaggregate the different elements. 
As expenditure is based on local needs and priorities, a 
substantial amount of programme expenditure is delegated 
to a local level where agencies have discretion over 
expenditure decisions and monitoring requirements are kept 
to a minimum wherever possible. This means that collation 
of a detailed breakdown of labelled spending by COFOG 
categories or by Reuter’s drug programme divisions would 
only be possible by placing additional burdens on local 
agencies.
In Ireland, it was much easier to categorise drug-related 
public expenditure by COFOG functions than by Reuter’s 
programme definition, and it was stated that adopting the 
framework of effects recommended by Reuter would require 
(i) an educational effort with planners and budget holders 
to ensure understanding and acceptance of the nuances 
of the different categories, and (ii) changes in the design, 
monitoring and evaluation of interventions. 
Non-labelled expenditure
As introduced before, unfortunately not all drug-related 
expenditure is identified as such in national budgets or year-
end reports. To overcome this problem, the solution either 
involves improving budgetary accountability (unlikely in the 
short term) or setting up specific approaches to estimate the 
amount expended in specific activities embedded in other 
programmes and interventions. In this case, non-labelled 
Figure 2: Labelled drug expenditure (in percentages) by Reuter’s 
programme classiﬁ cation
 Prevention Treatment Enforcement Harm reduction
Ireland
France
Luxembourg
Hungary
Portugal
Slovakia
Finland
UK
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Source: Reitox national reports, 2007.
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drug-related expenditure can be estimated following a 
straightforward modelling approach. 
Building on the experience of previous examples in the field 
(Origer, 2002; Kopp and Fenoglio, 2003; Postma, 2004) 
the methodology proposed is based on a gross (or top-down) 
costing approach. 
Three stages can be distinguished in costing; identification, 
measurement and valuation. Identification consists of 
listing the likely resource effects of the intervention as 
comprehensively as possible to help define the framework 
of the approach. As a first step in exploring a broader 
scope of drug-related expenditure, initial efforts focused on 
the COFOG groups that are most likely to accumulate the 
majority of public expenditure: police services, law courts, 
and prisons (under the public order and safety function), and 
medical products, appliances and equipment, outpatient 
services, and hospital services (under the health function). 
Measurement refers to the quantification of the resources 
used and the final stage refers to the valuation in monetary 
terms of these resources. Two strategies can be distinguished 
in measuring and valuation: micro- and gross-costing 
(Raftery, 2000). Micro-costing refers to a detailed analysis of 
the changes in resource use due to a particular intervention 
and, although precise, tends to be a costly exercise and 
runs the risk of being too specific to particular contexts. 
Also, whereas a detailed and comprehensive micro-costing 
would be desirable, its implementation in 30 countries is not 
practicable. Gross-costing is a top-down approach where a 
total budget is allocated to identified specific services ex ante 
and is the procedure used here.
In order to proceed with the gross-costing procedure, 
countries were asked to provide two elements: (i) overall 
government expenditure by selected 2nd level COFOG 
groups (see boxes on pages 12 and 16), and (ii) the 
attributable proportions reflecting the percentage of drug-
related activities within each of the selected COFOG groups. 
As details on 2nd level COFOG groups were not publicly 
available in many countries, the NFPs involved in providing 
non-labelled expenditure therefore opted to provide some 
alternative figures that would reflect overall expenditure 
in the areas concerned. This involved providing suitable 
attributable proportions that can be calculated in a number of 
different ways. This whole exercise involved some degree of 
creativity and was very time-consuming. The United Kingdom, 
for instance, used a combined estimation approach 
where some items were calculated through a gross-costing 
procedure, while others used micro-costing (5). The in-depth 
estimation performed by the UK means that its figures of non-
labelled public expenditure are much higher than those from 
other countries. This should be taken into consideration when 
reading the figures presented in tables and figures.
Table 5 shows the results from the estimation exercise on non-
labelled expenditure on public order and safety presented 
by nine countries (Czech Republic, France, Luxembourg, 
(1)
(5)  See the EMCDDA website at: http://www.emcdda.europa.eu/publications/selected-issues/public-expenditure
for a presentation of estimation strategies used by selected countries.
 
Amount (EUR million)
Total as a 
proportion of
Police Law courts Prisons Total COFOG (%) (1)
Czech Republic 110.5 16.0 36.4 162.9 7
France 571.2 13.1 270.2 854.5 4
Luxembourg 4.4 1.0 13.9 19.3 6
Hungary 16.5 6.9 7.6 31.0 2
Poland 4.4 92.4 22.5 119.3 3
Portugal n.a. 54.3 n.a. 54.3 2
Finland 20.8 4.7 32.6 58.1 2
United Kingdom 3 321.0 171.0 1 416.6 4 908.6 11
Norway 108.5 47.0 78.7 234.2 9
(1) Total general government expenditure on public order and safety function (COFOG 1st level) in 2005.
Source: Eurostat. Source of data other than (1): Reitox national reports, 2007.
Table 5: Non-labelled expenditure reported on public order and safety (COFOG 1st and 2nd levels) by country
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Hungary, Poland, Portugal, Finland, United Kingdom, 
Norway). Overall, 65 % of the expenses on public order 
and safety were devoted to police services, 29 % to prisons 
and 6 % to law courts. Most reporting countries (Czech 
Republic, France, Hungary, United Kingdom, Norway) fit 
into this sharing of expenditure among the COFOG groups, 
but some others showed a highest proportion of expenditure 
in prisons (Luxembourg, Finland), or in law courts (Poland). 
These differences can be explained by the different methods 
of estimation applied by the NFPs when providing this 
information.
By country, drug-related expenditure on police, law courts 
and prisons represented between 2 % and 11 % of total 
general government expenditure on public order and safety.
Table 6 presents the non-labelled expenditure estimated 
on health. None of the six countries providing information 
on this function were able to consider all four proposed 
groups (Medical products, Outpatient, Hospital and Public 
health services). This can be explained by a possible lack 
of access to indicators that can act as attributable fractions. 
The majority of reported expenditure was for hospital (53 %) 
and outpatient (45 %) services. Only the United Kingdom 
estimated outlays on medical products, and the Czech 
Republic and Luxembourg were the only countries providing 
estimations on public health. The Czech Republic’s data 
exclude expenditure covered by public health insurance; 
had this been included, estimations would increase by 
EUR 4.3 million for medicines, EUR 4.2 million for outpatient 
care and EUR 21.7 million for inpatient care.
The overall total amount estimated on health 
(EUR 828 million) by the Czech Republic, France, 
Luxembourg, Poland and the United Kingdom sharply 
contrasts with the amount estimated for public order and 
safety in the same countries: EUR 6.07 billion (Table 5). 
Consequently, by country, drug-related health expenditure 
represented quite a low proportion of total general 
expenditure on health (range 0.03 % to 0.51 %).
Total drug-related expenditure in Europe
Overall, 11 countries (Belgium, Czech Republic, France, 
Luxembourg, Hungary, Netherlands, Poland, Slovakia, 
Finland, Sweden, United Kingdom) accounted for a total 
amount of drug-related expenditure of EUR 15.4 billion. In 
the case of Sweden, not reporting on this Selected issue, 
the overall expenditure was taken from the EMCDDA 2007 
Annual report.
By country, total drug-related expenses ranged from EUR 
20 million to 8 700 million, representing between 0.10 % 
to 1.09 % of total general government expenditure, and 
between 0.05 % to 0.48 % as a proportion of GDP. The 
absence of comparable approaches in estimating the 
non-labelled component of total drug-related expenditure 
precludes any further comparison of individual figures among 
countries. For this reason, results by country are avoided in 
this section.
As displayed in Figure 3 (country identification is not 
provided to avoid misleading comparisons), when plotted, 
the total drug-related public expenditure reported shows 
a high linear association with GDP (R = 0.85): the higher 
the GDP, the higher the total drug expenses. The equation 
resulting from running a linear regression through the 
origin between the variables ‘Drug expenditure’ and ‘GDP’ 
 
Total as a 
proportion of
Medical 
products
Outpatient 
services
Hospital 
services
Public 
health Total
COFOG (%) (1)
Czech Republic – 0.4 3.1 0.4 3.9 0.06
France n.a. 349.6 287.1 n.a. 636.7 0.51
Luxembourg n.a. 2.1 3.5 0.1 5.8 0.36
Austria n.a. n.a. 24.1 n.a. 24.1 0.14
Poland n.a. 2.1 0.8 n.a. 2.8 0.03
United Kingdom 17.8 32.0 129.4 n.a. 179.2 0.14
(1) Total general government expenditure on Health function (COFOG 1st level) in 2005. 
Source: Eurostat. Source of data other than (1): Reitox national reports, 2007.
Amount (EUR million)
Table 6: Non-labelled expenditure reported on Health (COFOG 1st and 2nd levels) by country
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takes the form: ‘Drug expenditure = 0.003 * GDP’ (95 % 
confidence interval for B = 0.002 to 0.004) — this is 
Equation 1. This means that on average, for each million 
EUR of GDP in a country, EUR 3 000 is publicly spent on 
drug-related matters (95 % confidence boundaries would be 
between EUR 2 000 and 4 000 in this example).
This level of GDP expenditure (0.3 %) is much higher than 
the value suggested by the seminal contributions provided 
by Kopp and Fenoglio (2003). According to their estimates, 
public expenditure related to drugs at the time generally 
represented about 0.05 % of GDP (range 0.02 %–0.13 %). 
A later work on the topic by Postma (2004) confirmed the 
trends suggested by Kopp and Fenoglio on overall public 
expenditure in Europe, with most of the percentage of GDP 
ranging from 0.02 % to 0.15 %. These differences are 
certainly explained by the lack of figures for the countries 
considered at the time. The current report is the result of a 
more comprehensive and accurate analysis of expenditure, 
mainly due to the dual approach based on the identification 
of labelled and non-labelled expenditure. 
Estimation of total public expenditure in Europe
Previously, the total drug-related public expenditure by 
European countries in 2005 was calculated to lie somewhere 
between EUR 13 billion and EUR 36 billion (EMCDDA, 
2007). This figure was estimated by extrapolating the 
total drug-related expenditure of six countries (Belgium, 
Hungary, the Netherlands, Finland, Sweden and the 
United Kingdom) to the other under-reporting states. With 
the supplementary information provided by the Czech 
Republic, France, Luxembourg, Poland and Slovakia, and 
the new data provided by the United Kingdom, a single 
point estimate and new confidence interval (CI) has been 
calculated. By applying Equation 1 to the countries without 
current information on total expenditure, the new estimate of 
total public expenditure in Europe is EUR 34 billion (95 % 
confidence interval EUR 28 billion to EUR 40 billion).
Figure 3: Scatter plot showing the linear relation between total 
drug-related expenditure and GDP (EUR million)
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Source: Eurostat, 2005 (GDP).
  Reitox national reports, 2007 (total drug-related expenditure).
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Several countries have a considerable amount and quality 
of information on drug-related public expenditure that they 
make available, facilitating public analysis and debate. 
Overall, EUR 15.4 billion of drug-related public expenditure 
was identified in 11 countries in the year 2005, representing 
between 0.05 % and 0.48 % of their GDP. 
By extrapolating these figures to the rest of the countries 
(n = 19), the total drug-related public expenditure in Europe 
for 2005 was estimated to be EUR 34 billion (6) (95 % CI 
EUR 28 billion to EUR 40 billion), which is equivalent to 
0.3 % of the sum of the GDP of all of the countries (95 % CI 
0.2 %–0.4 %). This means that on average, for each 
EUR 1 million of a European country’s GDP in 2005, 
EUR 3 000 were publicly spent on drug-related matters. 
This represents an average expenditure of EUR 60 per 
European citizen per year. 
For labelled expenditure, the percentage of total expenditure 
explicitly labelled as drug-related in the budget and/or 
fiscal year-end accountancy reports consulted varied from 
1 % to 47 %. This large variation implies unequal levels 
of budget accountability on drug-related issues across 
European countries. Belgium and the Netherlands presented 
information on labelled and non-labelled expenditure at an 
aggregate level. No information on labelled expenditure was 
available for Bulgaria, Spain, Italy, Latvia, Sweden, Turkey 
and Norway. 
Labelled expenditure identified came mainly from the 
COFOG functions for health (67 %) and public order and 
safety (22 %). This pattern of labelled expenditure was 
confirmed when disbursements were classified according 
to programme purpose using Reuter’s (2006) definition: 
treatment programmes accounted for the majority of the 
outlays, followed by enforcement and prevention. A very tiny 
fraction of expenditure was identified as harm reduction. 
Prisons (31 %) and police services (16 %) covered the 
majority of labelled expenditure on public order and safety, 
while law courts accounted for only 0.06 %. On health, 
labelled expenditure related mainly to outpatient (68 %) and 
hospital (16 %) services, followed by medical products (7 %) 
and public health services (7 %). 
In contrast with these findings, the non-labelled estimations 
obtained suggest a different balance in the allocation of 
money between health and public order and safety. The 
overall total amount estimated on health (EUR 828 million) 
sharply contrasts with the amount estimated by the same 
countries on public order and safety (EUR 6.07 billion). By 
country, while non-labelled drug-related expenditure on 
police services, law courts and prisons represented between 
2 % and 11 % of total general government expenditure 
on public order and safety, the same percentages ranged 
only from 0.15 % to 1.25 % in the case of labelled 
expenditure on the same functions. The range of percentages 
over the total general expenditure on health were more 
comparable (0.03 %–0.51 % of non-labelled expenditure 
versus 0.02 %–0.8 % of labelled). This means that, despite 
public order and safety functions attaining higher levels 
of expenditure than health functions, health expenditure is 
more present in accountancy documents. Thus it can be said 
that, in general, health expenditure on drug-related issues is 
more distinct than expenditure allocated to law enforcement 
issues. Although this can easily be explained by the fact 
that expenditure on public order and safety tends to be 
embedded in broader and more general programmes of 
action against crime, one must remember that an assessment 
of the efficiency of government action is not feasible without 
a clear and well-defined formulation and classification 
of expenditure, where costs are properly identified in the 
relevant budget appropriations. The budget is the financial 
mirror of government policy; if the budget excludes important 
expenditure, there can be no assurance that scarce resources 
are allocated to priority programmes and that proper control 
and public accountability are enforced. 
Limitations of the study 
and future developments
The figures presented in this Selected issue should be taken 
as indicative and not definitive. Unfortunately, budget lines 
on drug-related issues are still too generic, too aggregated, 
over-inclusive, or simply unidentifiable, making labelled 
expenditure a sub-estimated fraction of the total expenditure 
identified. 
Conclusions and recommendations
(1)
(6)  This figure only represents general government expenditure. The total cost to society is likely to be much higher.
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(1)
(7)  USD to EUR Interbank rate average (365 days) in 2005: 0.80
(8)  In 2005, the total population for the 30 countries covered by this study was 572 million (Source: Eurostat), while the USA population for the same year was just 
under 300 million (Source: US Census Bureau).
The enticement of placing European expenditure identified in 
an international perspective is high, but the incompleteness 
of the current data precludes it. For instance, while the total 
amount of labelled expenditure reported by the countries 
covered by this study totalled EUR 2.42 billion, its labelled 
counterpart in the United States of America (USA), the 
Federal Drug Control Spending, amounted to EUR 10.08 
billion (USD 12.6 billion (7)) for the same fiscal year 
(Carnevale Associates, 2008). The difference observed 
clearly illustrates the non-comparability of the figures (8). 
The lack of standardised, complete estimations on 
non-labelled expenditure further contributes to the non-
comparability of results across countries. For example, for 
the present report NFPs were requested to provide, on a 
voluntary basis, the elements needed to estimate non-labelled 
expenditure. Eleven countries (37 % of the total) reported 
estimations on the public order and safety government 
function, and nine countries (30 % of the total) on the health 
function. The estimation strategies employed by these 
reporting countries were very varied in both depth and 
breadth, making direct comparisons of figures by country 
inappropriate. As already mentioned earlier in this report, 
the UK NFP provided the most exhaustive estimation exercise 
of all the countries, including elements of estimation that went 
beyond those originally requested. As a result, the UK figures 
of non-labelled public expenditure are much higher than 
other countries. This fact clearly draws attention to the need 
for further standardisation of the non-labelled component of 
public spending. 
 Furthermore, the disbursements identified here mainly refer 
to public expenditure made at central government level 
(regional and local government expenditure accounted for 
just 9 % of the total labelled expenditure identified); the 
future inclusion of sub-national government expenditure 
will certainly increase the amounts of public expenditure 
presented in this report. 
Caution is also needed when considering the conclusions 
obtained from the results of the regression analysis of GDP 
to total public expenditure (Equation 1). Drug-related public 
expenditure is a component of GDP, thus, all things being 
equal, an increase of public drug-related expenditure will 
raise GDP by the same amount. The calculation in Equation 
1 is based on the assumption that drug-related public 
expenditure depends on a country’s GDP. Is this hypothesized 
causal relationship plausible? The statistically significant 
regression results found do not necessarily establish a 
causal relationship between GDP and public expenditure. 
Although the statistical computations used to produce the 
estimated measure of association (R=0.85) are appropriate, 
the estimate itself may be biased. Such bias may result 
from not considering in the analysis other variables that 
can account for the observed association, such as the size 
of the drug problem in the country, the political orientation 
of government, or the model of state. The resulting biases 
can distort the true value of the correlation coefficient and 
lead to a false conclusion on the relationship between the 
variables involved in the analysis. Should this occur, a deeper 
assessment of the plausibility of the causal relationship 
between GDP and total expenditure must be performed. 
Studies on public expenditure require a fair amount of 
analytical work for the labelled component, and require a 
certain degree of creativity as far as non-labelled expenditure 
is concerned (Luxembourg National report, 2007). 
Altogether, this means that comprehensive approaches to 
precisely estimate public expenditure are currently beyond 
the technical, resource or human capabilities of some Reitox 
national focal points. This situation should be resolved 
over time by providing simple, clear and straightforward 
guidelines on how to proceed in identifying labelled and non-
labelled expenditure. The EMCDDA can play a leading role 
in this action by compiling the different strategies available 
for identifying expenditure, based on the experiences 
reported by the countries who have already carried out this 
exercise. 
To conclude, work must continue in order to build upon and 
enhance the data available and to complete and refine 
figures on public expenditure. The twofold methodology 
proposed and implemented by the EMCDDA in this Selected 
issue, although preliminary, has proven to be feasible and 
scientifically robust. 
The flip side of drug-related public 
expenditure
Public expenditure figures are ultimately intended to enhance 
policymakers’ decision-making on drug policy. But decision-
makers must be very careful and refrain from taking decisions 
based on raw public expenditure figures without carefully 
trading-off the alternatives involved or without a sufficient 
evaluation of the possible consequences of spending 
choices. The simple identification of an area of low (or 
high) expenditure cannot in itself suggest inefficiency. An 
inefficient allocation of resources exists when the resources 
concerned could generate greater benefits if used elsewhere, 
but without an understanding of the benefits gained, it is not 
possible to assess whether expenditure in a particular area 
is efficient or not (Maynard, 2004). As introduced in the first 
am805490Int.indd   224 26/06/08   11:26:23
25
Towards a better understanding of drug-related public expenditure in Europe
section of this report, public expenditure studies represent 
important intermediate stages in economic evaluation since 
they provide an understanding of the size and composition 
of cost programmes and interventions. Public expenditure 
approaches must then be complemented by undertaking 
economic evaluations where expenditure is considered in the 
perspective of the benefits obtained by its allocation.
In addition, another consideration is that public expenditure 
may not be the only way to deliver certain services or to 
achieve particular drug policy objectives. For instance, in 
many countries health and social policy interventions are 
likely to involve private stakeholders (i.e. patients, families, 
insurance companies, NGOs). International comparisons 
of resources devoted to achieving drug policy objectives in 
these areas will be highly misleading if no account is taken of 
such costs.
There is still a great need for further research and investment 
in this particular field of drug economics in Europe. 
Nevertheless, with an increasing international interest in 
the development of the discipline and more economic and 
human resources allocated to it, the European knowledge 
base in the area will increase steadily over time.
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Budget (1)
The official statement that the general government makes 
about how much public expenditure there will be in the next 
fiscal year and how it will be financed. 
COFOG (2)
The Classification of the Functions of Government. This 
is an international categorisation tool used to identify the 
socioeconomic objectives the general government units aim 
to achieve through a range of outlays.
Direct drug-related costs (5)
General drug-related costs can be divided into two major 
categories: direct and indirect. Direct costs are those costs for 
which payments are made, and typically include expenditure 
in the areas of prevention, treatment, harm reduction and law 
enforcement. 
Economic evaluation (3)
The comparative analysis of alternative actions in terms of 
both their costs and consequences. 
Effectiveness (2)
The extent to which an action achieves its intended purpose.
Efficiency (1)
The extent to which maximum output is achieved from a given 
level of resources used to produce an action. 
GDP (1)
The gross domestic product is an economic indicator that 
quantifies the economic activity of a country. It is calculated 
by adding the market value of all goods and services 
produced by the economy during a given period, including 
private consumption, investment, public expenditures, private 
inventories, and the foreign trade balance (exports minus 
imports).
General government (2)
The general government of a country is the set of institutional 
units producing non-market services for individual/collective 
consumption and redistributing income and wealth. It mainly 
consists of central, regional and local government units 
together with social security funds. In addition, it includes 
non-profit institutions engaged in non-market production that 
are controlled and mainly financed by government units or 
social security funds.
Gross costing (4)
A costing method that follows a ‘top-down’ approach where 
a global cost-indicator is used to determine the total costs of a 
cluster of activities. 
Indirect drug-related costs (5)
Indirect costs are the value of productive services not 
performed because of drug use. These typically consist of lost 
productivity due to drug-related morbidity and mortality. 
Glossary
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Labelled drug-related expenditure (5)
The ex-ante planned public expenditure made by the 
general government in the budget that reflects the voluntary 
commitment of a country in the field of drugs.
Micro costing (4)
A costing method that follows a ‘bottom-up’ approach that 
involves the detailed inventory, measurement and valuation 
of all the separate cost-items involved in a given activity. 
Non-labelled drug-related expenditure (5)
The non-planned, ex-post, public expenditure faced by 
the general government in tackling with drugs, that is not 
identified as drug-related in the budget. 
Opportunity cost (2)
The opportunity cost of a resource equals the value of the 
forgone benefits that would be obtained if that resource 
would have been available for its best alternative use. 
Public expenditure (1)
The value of goods and services bought by the general 
government of a country in order to execute each of its 
socioeconomic functions. 
Social cost (5)
Drug-related social costs are the total of all of the costs 
to society, direct and indirect, caused by drug use. The 
output, expressed in monetary terms, is an estimate of the 
total burden that drug use places on society. The primary 
aim of social cost calculations is to weigh the burden that 
drug problems pose on society against the cost to society of 
addressing these problems.
Total drug-related public expenditure (5)
The value of all the goods and services bought by the general 
government of a country in tackling drugs. It is calculated by 
adding labelled and non-labelled drug-related expenditure. 
The estimation of total drug-related public expenditure is a 
different exercise from that of estimating social costs. Total 
drug-related public expenditure represents only a proportion 
of social costs, mainly in the form of direct costs; indirect 
costs are explicitly excluded, as are costs from private 
stakeholders (e.g. private health-insurance companies).
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About the EMCDDA
The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 
is one of the European Union’s decentralised agencies. Established in 1993 
and based in Lisbon, it is the central source of comprehensive information 
on drugs and drug addiction in Europe.
The EMCDDA collects, analyses and disseminates factual, objective, reliable 
and comparable information on drugs and drug addiction. In doing 
so, it provides its audiences with an evidence-based picture of the drug 
phenomenon at European level.
The Centre’s publications are a prime source of information for a wide 
range of audiences including policymakers and their advisors; professionals 
and researchers working in the field of drugs; and, more broadly, 
the media and general public.
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